戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 thogenesis of asthma and chronic obstructive pulmonary disorder.
2 epresents a diverse and challenging group of pulmonary disorders.
3 nd is linked to asthma and an array of extra-pulmonary disorders.
4 ucus hyperproduction associated with chronic pulmonary disorders.
5 eristics of both obstructive and restrictive pulmonary disorders.
6 de developing new therapeutic strategies for pulmonary disorders.
7 enetic modifications that might translate to pulmonary disorders.
8  representing pathologically related primary pulmonary disorders.
9 implicated in a number of cardiovascular and pulmonary disorders.
10 therapeutic option for a number of end-stage pulmonary disorders.
11 such as dependence/addiction, psychosis, and pulmonary disorders.
12 ful targets for cell or gene replacement for pulmonary disorders.
13 icated in human disease processes, including pulmonary disorders.
14 n implicated in the etiology of a variety of pulmonary disorders.
15 d in subjects with CF and other inflammatory pulmonary disorders.
16 onates and children with diverse cardiac and pulmonary disorders.
17 tial diagnostic tool in the study of various pulmonary disorders.
18 , many features are reminiscent of the fatal pulmonary disorder alveolar capillary dysplasia.
19 ransplantation or during treatment of severe pulmonary disorders and sepsis.
20 ells are effectors of injury in a variety of pulmonary disorders and syndromes.
21 well as cystic fibrosis, chronic obstructive pulmonary disorder, and asthma in the pulmonary tissues.
22 nosinusitis, asthma, and chronic obstructive pulmonary disorder are characterized by inflammation and
23 , diabetes, current smoking, and obstructive pulmonary disorders are also important independent risk
24                                              Pulmonary disorders are the most frequent cause of death
25 deficient (SP-C -/-) mice developed a severe pulmonary disorder associated with emphysema, monocytic
26 life-saving intervention for several primary pulmonary disorders complicated by severe lung dysfuncti
27 brosis (IPF) is a chronic fibroproliferative pulmonary disorder for which there are currently no trea
28 earch investigations of pediatric airway and pulmonary disorders for nearly 25 years.
29     Gene therapy as a treatment modality for pulmonary disorders has attracted significant interest o
30        Cystic fibrosis (CF), a common lethal pulmonary disorder in Caucasians, is caused by mutations
31 fibrosis, the most commonly inherited lethal pulmonary disorder in Caucasians, is caused by mutations
32 tures and mechanisms of renal dysfunction in pulmonary disorders in relation to respiratory acidosis,
33 o the pathogenesis of many acute and chronic pulmonary disorders, including bronchopulmonary dysplasi
34       Lymphangioleiomyomatosis (LAM), a rare pulmonary disorder, manifests as an abnormal neoplastic
35 ell homeostasis underlie the pathogenesis of pulmonary disorders previously considered idiopathic, pr
36 understanding of the pathogenesis of diverse pulmonary disorders previously considered idiopathic.
37     Fibrosis and apoptosis are juxtaposed in pulmonary disorders such as asthma and the interstitial
38    Goblet cell metaplasia accompanies common pulmonary disorders that are prone to recurrent viral in
39 and mechanical ventilation for PCP and other pulmonary disorders was associated with a high mortality
40  Absence of SP-C caused a severe progressive pulmonary disorder with histologic features consistent w

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。